gms | German Medical Science

23rd Annual Meeting of the German Retina Society

German Retina Society

24.09. - 25.09.2010, Freiburg

Article

Send article

How fast declines the Avastin concentration in eye? Measurements of the pharmacokinetics of Bevacizumab in human eyes

Meeting Abstract

Search Medline for

  • Carsten H. Meyer - University Eye Clinic Bonn
  • T. Krohne - University Eye Clinic Bonn
  • F.G. Holz - University Eye Clinic Bonn

German Retina Society. 23rd Annual Conference of the German Retina Society. Freiburg i. Br., 24.-25.09.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. Doc10rg47

doi: 10.3205/10rg47, urn:nbn:de:0183-10rg479

This is the English version of the article.
The German version can be found at: http://www.egms.de/de/meetings/rg2010/10rg47.shtml

Published: September 21, 2010

© 2010 Meyer et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Objectives: The intraocular pharmacokinetics of a single intravitreal injection Bevacizumab in the human eye remains unknown.

Methods: In a prospective case series including 30 eyes of 30 patients with clinically significant cataract and simultaneous macular edema due to diabetic maculopathy, AMD or retinal vein occluision in the same eye, all patients received an intravitreale injection of 1.5 mg Bevacizumab. After 1 to 53 days an anterior chamber sample was obtained during an elective cataract operation. The concentration of unbound Bevacizumab in the anterior chamber sample was determined by ELISA.

Results: The highest concentration (cmax 33.3 µg/ml (area 16,6–42.5 µg/ml)) of unbound Bevacizumab in the anterior chamber was measured a day after the injection, followed by a rdecline in a mono exponential function. The linear regression analysis showed a half time of 9.82 days (R2=0.81).

Summary: Reinjections intervals of 4 weeks are necessary to maintain a concentration above the biological active concentration. Two additional studies investigate the pharmakokinetic effectes of Lucentis as well as double dose Bevacizumab. The corresponding half time are presented.